Cargando…

Interventional hepatic apoC-III knockdown improves atherosclerotic plaque stability and remodeling by triglyceride lowering

Apolipoprotein C-III (apoC-III) is a critical regulator of triglyceride metabolism and correlates positively with hypertriglyceridemia and cardiovascular disease (CVD). It remains unclear if therapeutic apoC-III lowering reduces CVD risk and if the CVD correlation depends on the lipid-lowering or an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramms, Bastian, Patel, Sohan, Sun, Xiaoli, Pessentheiner, Ariane R., Ducasa, G. Michelle, Mullick, Adam E., Lee, Richard G., Crooke, Rosanne M., Tsimikas, Sotirios, Witztum, Joseph L., Gordts, Philip L.S.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310539/ https://www.ncbi.nlm.nih.gov/pubmed/35653195 http://dx.doi.org/10.1172/jci.insight.158414

Ejemplares similares

ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance
por: Ramms, Bastian, et al.
Publicado: (2019)

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
por: Alexander, Veronica J, et al.
Publicado: (2019)

The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
por: Borén, Jan, et al.
Publicado: (2020)

Proteoglycans in Obesity-Associated Metabolic Dysfunction and Meta-Inflammation
por: Pessentheiner, Ariane R., et al.
Publicado: (2020)

APOC3: Triglycerides do matter
por: Hassan, Mohamed
Publicado: (2014)

Very-Low-Density Lipoprotein–Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III
por: Pechlaner, Raimund, et al.
Publicado: (2017)

APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism
por: Giammanco, Antonina, et al.
Publicado: (2023)

Short hydrocarbon stapled ApoC2-mimetic peptides activate lipoprotein lipase and lower plasma triglycerides in mice
por: Sviridov, Denis, et al.
Publicado: (2023)

AAV-Mediated ApoC2 Gene Therapy: Reversal of Severe Hypertriglyceridemia and Rescue of Neonatal Death in ApoC2-Deficient Hamsters
por: Yang, Chun, et al.
Publicado: (2020)

ApoC-III and visceral adipose tissue contribute to paradoxically normal triglyceride levels in insulin-resistant African-American women
por: Sumner, Anne E, et al.
Publicado: (2013)

Sex differences in HDL ApoC-III in American Indian youth
por: Blackett, Piers R, et al.
Publicado: (2012)

microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production
por: Dong, Jianjie, et al.
Publicado: (2020)

Dissociation Between APOC3 Variants, Hepatic Triglyceride Content and Insulin Resistance
por: Kozlitina, Julia, et al.
Publicado: (2011)

ApoC-III is a novel inducer of calcification in human aortic valves
por: Schlotter, Florian, et al.
Publicado: (2021)

ApoC3 is expressed in oocytes and increased expression is associated with PCOS progression
por: Zhou, Jiahe, et al.
Publicado: (2023)

A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans
por: Timpson, Nicholas J., et al.
Publicado: (2014)

Targeting ApoC3 Paradoxically Aggravates Atherosclerosis in Hamsters With Severe Refractory Hypercholesterolemia
por: Xu, Yitong, et al.
Publicado: (2022)

New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
por: Kim, Ji Yoon, et al.
Publicado: (2023)

Ethnic differences in ApoC-III concentration and the risk of cardiovascular disease: No evidence for the cardioprotective role of rare/loss of function APOC3 variants in non-Europeans
por: Rout, Madhusmita, et al.
Publicado: (2022)

Erratum: A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans
por: Timpson, Nicholas J., et al.
Publicado: (2015)

Frequency and phenotype consequence of APOC3 rare variants in patients with very low triglyceride levels
por: Crawford, Dana C., et al.
Publicado: (2018)

Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements
por: Yeang, Calvin, et al.
Publicado: (2021)

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
por: Taskinen, Marja-Riitta, et al.
Publicado: (2019)

The adaptor protein PID1 regulates receptor-dependent endocytosis of postprandial triglyceride-rich lipoproteins
por: Fischer, Alexander W., et al.
Publicado: (2018)

Glycocalyx engineering with heparan sulfate mimetics attenuates Wnt activity during adipogenesis to promote glucose uptake and metabolism
por: Trieger, Greg W., et al.
Publicado: (2023)

Triglycerides and Residual Atherosclerotic Risk
por: Raposeiras-Roubin, Sergio, et al.
Publicado: (2021)

Feasibility of ApoC1 serum levels as tumor biomarker in glioblastoma patients: a pilot study
por: Hilbert, Michelle, et al.
Publicado: (2022)

Metabolic characterisation of disturbances in the APOC3/triglyceride-rich lipoprotein pathway through sample-based recall by genotype
por: Corbin, Laura J., et al.
Publicado: (2020)

APOC3 rs2070667 Associates with Serum Triglyceride Profile and Hepatic Inflammation in Nonalcoholic Fatty Liver Disease
por: Xu, Qing-Yang, et al.
Publicado: (2020)

Impaired LDL Receptor-Related Protein 1 Translocation Correlates with Improved Dyslipidemia and Atherosclerosis in apoE-Deficient Mice
por: Gordts, Philip L.S.M., et al.
Publicado: (2012)

Apoc2 loss-of-function zebrafish mutant as a genetic model of hyperlipidemia
por: Liu, Chao, et al.
Publicado: (2015)

Treatment with Volanesorsen, a 2′-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting APOC3 mRNA, Does Not Affect the QTc Interval in Healthy Volunteers
por: Watts, Lynnetta M., et al.
Publicado: (2020)

Apolipoprotein Gene Polymorphisms (APOB, APOC111, APOE) in the Development of Coronary Heart Disease in Ethnic Groups of Kazakhstan
por: Berkinbayev, S, et al.
Publicado: (2014)

APOE ɛ4 allele and TOMM40‐APOC1 variants jointly contribute to survival to older ages
por: Kulminski, Alexander M., et al.
Publicado: (2022)

Tryptase Promotes Atherosclerotic Plaque Haemorrhage in ApoE-/- Mice
por: Zhi, Xiuling, et al.
Publicado: (2013)

Associations of the APOE ε2 and ε4 alleles and polygenic profiles comprising APOE-TOMM40-APOC1 variants with Alzheimer’s disease biomarkers
por: Kulminski, Alexander M., et al.
Publicado: (2022)

Genetic Variations, Triglycerides, and Atherosclerotic Disease
por: Tada, Hayato, et al.
Publicado: (2019)

40 Years of the APOC Partnership
por: Roungou, Jean-Baptist, et al.
Publicado: (2015)

Associations among Race/Ethnicity, ApoC-III Genotypes, and Lipids in HIV-1-Infected Individuals on Antiretroviral Therapy
por: Foulkes, Andrea S, et al.
Publicado: (2006)

APOE and APOC1 gene polymorphisms are associated with cognitive impairment progression in Chinese patients with late-onset Alzheimer's disease
por: Zhou, Qin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_v2d7utg3tp3pv5l3qvvg4vu3ut